Home Tags Clinical Trials
Clinical Trials Related Content
The REACH study found that 97% of women and girls in Uganda, South Africa and Zimbabwe are happy to work with HIV prevention methods - globally, half of all people living with HIV are women.
New data from Phase Three of the Sinovac vaccine trial shows that the drug is now performing at 83.5%.
Pfizer say they will develop a new COVID vaccine to function as a booster against the Delta variant.
The team will have results to discuss in April, 2022 - they nurse the hope that this HIV vaccine could stop different geographical strains, after 40 years of no cure.
A study released yesterday (28 June) found that it would be safe to mix Pfizer and AstraZeneca doses, which could speed up UK vaccine roll-out if adopted.
The World Health Organisation on Friday (18 June) said that the Delta variant, originating in India, would be globally dominant due to "significantly increased transmissibility".
Professor Dr Freimut Schliess, Director of Science & Innovation at the Profil Institut für Stoffwechselforschung GmbH, explores how the MDR will impact clinical trials.
Dr Mathias Allemand and Dr Patrick L. Hill discuss the complex factors contributing to healthy ageing, and explore the ways in which personality traits can be considered as a component.
The German-made CureVac vaccine has given a result of 47% efficacy, much lower than expected - now, the proposed delivery of 225 million doses to the EU is at risk.
A new study found that the Novavax vaccine was 93.2% effective against the Alpha variant - with no clarification about vaccine performance against the Delta variant.
The UK today (28 May) approves use of the single-dose Johnson & Johnson vaccine that provides enough protection against the virus in one injection.
Over the last three months, scientists have been tracing rare instances of blood clots in veins in connection to the AstraZeneca COVID vaccine - now, they have the first evidence of arterial blood clots, which can cause stroke.
The Moderna vaccine has been found to be 100% effective against COVID-19 in 12-17 year olds, according to new data from the TeenCOVE study.
Public Health England have found that both Pfizer and AstraZeneca vaccines against the Indian variant would have an efficacy of 33.5% in one dose.
On Wednesday (12 May), the CDC announced that the Pfizer vaccine could now be given to 12-15 year olds - effective immediately for 17 million adolescents.
The CureVac mRNA vaccine is currently in final stages of clinical trials - but it is expected to perform like Pfizer and Moderna, with the bonus of surviving at ordinary refrigeration temperatures.
Pfizer could make their COVID vaccine available to 12-year-olds in Europe from June, after clinical trials in March showed 100% efficiency for those aged 12 to 15.
The study found that missing a second COVID dose could "prolong" the pandemic, with more than 5 million people in the US not taking their scheduled dose.
The city of Manaus was hit so overwhelmingly by the Brazilian COVID mutation, it was believed that 75% of the population had COVID - what new truths are scientists learning about this powerful variant?
New data from the UK's vaccination programme suggests that one in four people get Pfizer and AstraZeneca vaccine side effects - with most peaking in the first 24 hours, then gone in two days.